Our broad pipeline includes multiple targeted therapies that harness the immune system and target specific molecular pathways.
* Denotes a Core Product.
** Each progress bar denotes the most advanced clinical trial of each drug candidate.
# Denote drug candidates of which the ownerships were transferred to our Company from Crown Bioscience International.
^ Denote drug candidates that we in-licensed from third parties.
(1) "China" means the People’s Republic of China, but for the purposes of this document (including this pipeline chart) and for geographical reference only, except where the context requires otherwise, references in this document to China do not include Hong Kong, Macau and Taiwan.“ "Greater China" means China, Hong Kong, Macau and Taiwan.
(2) NSCLC: non-small cell lung cancer; GBM: secondary glioblastoma multiforme; RCC: renal cell carcinoma; AML: acute myeloid leukemia; MM: multiple myeloma; GI: Gastroenterological